Coverage Initiated by Mizuho for BridgeBio Pharma (NASDAQ:BBIO)

Stock analysts at Mizuho initiated coverage on shares of  BridgeBio Pharma (NASDAQ:BBIO) in a report issued on wednesday. The brokerage set a Buy rating on the Medical stock. A price-to-earnings ratio of #N/A and a beta of #N/A. BridgeBio Pharma has a twelve month low $37.29 of  and a twelve month high of $73.50.

Shares of BridgeBio Pharma traded up $1.91 on wednesday, reaching $48.55. 981191 shares of the stock traded hands, compared to its average volume of 958955. Shares of BridgeBio Pharma were trading at $48.55 on wednesday. The firm’s 50 day moving average is $$49.58 and its 200 day moving average is $58.22.BridgeBio Pharma  has a 12 month low of $46.50 and a 12 month high of $73.50. While on yearly highs and lows, BridgeBio Pharma’s today has traded high as $48.64 and has touched $46.50 on the downward trend. See More Analyst Rating at: RATING

BridgeBio Pharma Earnings and What to expect: 

BridgeBio Pharma last posted its earnings data on August 5th, 2021. The reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.31. The firm had revenue of $54 million for the quarter, compared to analysts’ expectations of $24.93 million. Its revenue for the quarter was up 5399900.0% on a year-over-year basis. BridgeBio Pharma has generated ($3.80) earnings per share over the last year (($3.83) diluted earnings per share). Earnings for BridgeBio Pharma are expected to decrease in the coming year, from ($3.68) to ($3.72) per share. BridgeBio Pharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for BridgeBio Pharma are expected to decrease in the coming year, from ($3.68) to ($3.72) per share. The P/E ratio of BridgeBio Pharma is -12.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of BridgeBio Pharma is -12.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. BridgeBio Pharma has a P/B Ratio of 55.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

BridgeBio Pharma (NASDAQ:BBIO) Moving Average Technical Analysis

5 day Moving Average is $46.14 And 5 day price change is $3.64 (8.11%)  with average volume for 5 day average is 812,500. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $48.05 and 20 day price change is $0.09 (0.19%) and average 20 day moving volume is 1,047,650. 50 day moving average is $49.58  and 50 day price change is -$4.24 ( -8.03%)  and with average volume for 50 days is : 847,696. 200 day moving average is $58.22  and 200 day price change is -$20.93 (-30.12%)  and with average volume for 200 days is : 906,332.

Other owners latest trading in BridgeBio Pharma :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 57,297 which equates to market value of $3.49M and appx 0.00% owners of BridgeBio Pharma
  • On 8/17/2021 shares held by Wexford Capital LP were 50,000 which equates to market value of $3.05M and appx 0.50% owners of BridgeBio Pharma
  • On 8/17/2021 shares held by Castleark Management LLC were 46,457 which equates to market value of $2.83M and appx 0.10% owners of BridgeBio Pharma
  • In total Institutional ownership equates to Institutional Ownership Percentage: 94.88% for BridgeBio Pharma

See More Analyst Rating at: RATING